Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE
Authors
Haran, A. M.Jain, Y.
Hambrock, T.
Murphy, L. R.
Cook, A.
Brown, L. C.
Hoyle, Alex P
Sachdeva, Ashwin
Ali, S. A.
Amos, C. L.
Sydes, M. R.
Attard, G.
Parmar, M. K.
James, N. D.
Clarke, Noel W
Affiliation
Genito-Urinary Cancer Research Group, The University of Manchester, Manchester,UKIssue Date
2022
Metadata
Show full item recordCitation
Haran AM, Jain Y, Hambrock T, Murphy LR, Cook A, Brown LC, et al. Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE. Annals of Oncology. 2022 Sep;33(7):S1161-S2. PubMed PMID: WOS:000866211601616.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.1946Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.1946Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.1946